Acute pancreatitis classification
|
Acute pancreatitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Acute pancreatitis classification On the Web |
|
American Roentgen Ray Society Images of Acute pancreatitis classification |
|
Risk calculators and risk factors for Acute pancreatitis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Monish Thuvooru Muthu Kalyanaraman, M.B.B.S[2]
Classification
Overview
This microchapter covers the classification systems used to categorize acute pancreatitis by severity grade, morphologic subtype, clinical phase, and type of local complication. The two principal severity classification systems — the Revised Atlanta Classification (RAC, 2012) and the Determinant-Based Classification (DBC, 2012) — are detailed alongside the modified Marshall scoring system used to define organ failure. Etiologic classification, prognostic scoring system performance (APACHE II, BISAP, Ranson criteria), imaging appearance of collections, and management of complications are addressed in their respective microchapters.
Clinical Phases
The RAC formally divides the clinical course of acute pancreatitis into two distinct phases, each with different pathophysiologic drivers and clinical implications:[1][2]
- Early phase (first 1–2 weeks): Driven by the host systemic inflammatory response to pancreatic injury. Clinical severity during this phase is determined by the presence and duration of organ failure triggered by cytokine cascades and SIRS, rather than by morphologic findings. Imaging is often not yet definitive for necrosis during this period.[1][3]
- Late phase (after weeks 1–2): Occurs only in patients with moderately severe or severe acute pancreatitis. Characterized by evolution of local complications (fluid collections, necrosis, infection) and persistent or recurrent organ failure. Morphologic criteria on imaging become essential for guiding management during this phase.[3][1]
This temporal framework is clinically important: during the early phase, only clinical parameters (organ failure, SIRS) guide severity assessment and treatment decisions; morphologic classification and imaging-based management become relevant in the late phase.[1]
Severity Classification Systems
Revised Atlanta Classification (2012)
The Revised Atlanta Classification (RAC) is the most widely adopted international consensus framework, replacing the original 1992 Atlanta Classification, which used only a two-tier system (mild vs. severe) with no intermediate category. The RAC introduced a three-tier severity system based on the presence and duration of organ failure and the presence of local or systemic complications:[1][4][5]
| Severity Grade | Definition | Approximate Frequency | Mortality |
|---|---|---|---|
| Mild | No organ failure at all (transient or persistent), and no local or systemic complications | ~80% | Low |
| Moderately severe | Transient organ failure (<48 h) and/or local complications | ~15% | Low–moderate |
| Severe | Persistent organ failure (≥48 h); single or multiorgan | ~5–10% | 20–40% |
Key points regarding the RAC:
- Systemic complications are defined as exacerbation of pre-existing comorbidities (e.g., chronic lung disease, heart failure).[6][1]
- Local complications include peripancreatic fluid collections, pancreatic/peripancreatic necrosis (sterile or infected), pseudocysts, and walled-off necrosis.[1]
- The 48-hour cutoff distinguishing transient from persistent organ failure was chosen because organ dysfunction that resolves within this window is associated with outcomes similar to mild disease, whereas dysfunction persisting beyond it correlates with substantially higher morbidity and mortality.[1][7]
- Severity is a dynamic classification — a patient initially classified as mild can rapidly decompensate into severe acute pancreatitis, necessitating continuous reassessment during the early phase.[7]
Determinant-Based Classification (2012)
The Determinant-Based Classification (DBC) is an alternative system that adds a fourth severity tier ("critical") and explicitly incorporates the infection status of necrosis as a determinant of severity, in addition to organ failure:[8][9]
| DBC Severity Grade | Definition |
|---|---|
| Mild | No (peri)pancreatic necrosis; no organ failure |
| Moderate | Sterile (peri)pancreatic necrosis and/or transient organ failure (<48 h) |
| Severe | Infected (peri)pancreatic necrosis or persistent organ failure (>48 h) |
| Critical | Infected (peri)pancreatic necrosis and persistent organ failure (>48 h) |
A nationwide retrospective multicenter cohort study found that both the RAC and DBC demonstrate comparable ability to distinguish worsening outcomes by increasing severity category.[10] The RAC remains more widely used in clinical practice and research, while the DBC's "critical" category may better identify the highest-risk subgroup (infected necrosis with persistent organ failure), which carries mortality rates of 30–50%.[10][8]
Comparison: Original Atlanta (1992) vs. Revised Atlanta (2012)
The original 1992 Atlanta Classification used a two-tier system (mild vs. severe) and included specific clinical thresholds (systolic blood pressure ≤90 mmHg, PaO₂ ≤60 mmHg, creatinine ≥2 mg/dL, gastrointestinal bleeding >500 mL/24 h) to define organ failure. The 2012 revision introduced several critical updates:[1][11][2]
- Addition of the moderately severe category — absent from the original classification — recognizing that transient organ failure and local complications without persistent organ failure represent an intermediate-risk group
- Adoption of the modified Marshall scoring system as the standardized tool for organ failure assessment (replacing the heterogeneous criteria of the original classification)
- Formal classification of four types of fluid collections (replacing ambiguous terms such as "pancreatic abscess" and "acute pseudocyst")
- Recognition of two clinical phases (early and late)
- Distinction between interstitial edematous and necrotizing pancreatitis as separate morphologic subtypes
Modified Marshall Scoring System
Organ failure in acute pancreatitis is defined and graded using the modified Marshall scoring system, which assesses three organ systems: respiratory, renal, and cardiovascular. A score of ≥2 in any one system defines organ failure.[5][7][12][6]
| Organ System | Score 0 | Score 1 | Score 2 (Organ Failure) | Score 3 | Score 4 |
|---|---|---|---|---|---|
| Respiratory (PaO₂/FiO₂) | >400 | 301–400 | 201–300 | 101–200 | ≤100 |
| Renal (serum creatinine, mg/dL) | <1.4 | 1.4–1.8 | 1.9–3.6 | 3.7–4.9 | >4.9 |
| Cardiovascular (SBP, mmHg) | >90 | <90, fluid responsive | <90, not fluid responsive | <90, pH <7.3 | <90, pH <7.2 |
- Transient organ failure: modified Marshall score ≥2 that resolves within 48 hours → defines moderately severe acute pancreatitis.[1][7]
- Persistent organ failure: modified Marshall score ≥2 lasting >48 hours → defines severe acute pancreatitis.[1][7]
- For non-ventilated patients, FiO₂ can be estimated from supplemental oxygen flow rate (room air = 21%; 2 L/min ≈ 25%; 4 L/min ≈ 30%; 6–8 L/min ≈ 40%; 9–10 L/min ≈ 50%).[5]
Morphologic Classification
Acute pancreatitis is divided into two morphologic subtypes based on the presence or absence of necrosis, best assessed by contrast-enhanced CT (CECT) performed ≥72 hours after symptom onset:[1][4][11][2]
Interstitial edematous pancreatitis
- Accounts for ~90–95% of cases[13]
- Diffuse or localized pancreatic enlargement due to inflammatory edema
- CECT: homogeneous parenchymal enhancement; peripancreatic fat stranding; possible peripancreatic fluid
- Generally self-limiting; most patients have mild disease
Necrotizing pancreatitis
- Occurs in ~5–10% of cases[4][10]
- Necrosis of pancreatic parenchyma, peripancreatic tissue, or both
- CECT: lack of parenchymal enhancement and/or heterogeneous peripancreatic collections containing necrotic debris
- Three anatomic patterns:[4][10]
- Combined pancreatic and peripancreatic necrosis (~45%)
- Peripancreatic necrosis alone (~45–50%) — generally better prognosis than parenchymal necrosis[3]
- Isolated pancreatic parenchymal necrosis (~5%, rare)
- Pancreatic necrosis is defined as nonenhancing parenchyma >3 cm or >30% of the gland[4]
- Necrosis may remain sterile or become infected; the extent of necrosis does not reliably predict infection risk — patients with sterile and infected necrosis are similarly likely to have organ failure[4][10]
- CECT may underestimate necrosis if performed within the first 48–72 hours[10][13]
Classification of Local Complications (Fluid Collections)
The RAC defines four types of pancreatic/peripancreatic collections based on the morphologic subtype of pancreatitis and time elapsed since disease onset. The terms "pancreatic abscess" and "acute pseudocyst" from the 1992 classification have been abandoned.[1][11][2]
| Collection Type | Pancreatitis Subtype | Timing | Contents | Wall |
|---|---|---|---|---|
| Acute peripancreatic fluid collection (APFC) | Interstitial edematous | ≤4 weeks | Homogeneous fluid | No defined wall |
| Pseudocyst | Interstitial edematous | >4 weeks | Homogeneous, amylase-rich fluid; no solid debris | Well-defined, non-epithelialized wall |
| Acute necrotic collection (ANC) | Necrotizing | ≤4 weeks | Heterogeneous; variable fluid and necrotic debris | No defined wall |
| Walled-off necrosis (WON) | Necrotizing | >4 weeks | Heterogeneous; fluid and encapsulated necrotic debris | Mature, enhancing capsule |
- APFCs are extrapancreatic, conform to retroperitoneal fascial planes, and usually resolve spontaneously.[8][14]
- Pseudocysts are rare after severe acute pancreatitis and thought to arise from pancreatic duct disruption in the absence of parenchymal necrosis. They are often mislabeled — many collections previously called "pseudocysts" are actually WON containing solid necrotic debris.[8][14][10]
- ANCs may be intrapancreatic or extrapancreatic, can be multiple, and are more likely to become infected than APFCs; the distinction between ANCs and APFCs typically becomes clear after the first week.[14]
- WON is the primary target for intervention when symptomatic or infected. Although the RAC states WON typically develops ≥4 weeks after onset, a multicenter study found that 43% of demarcated collections had already developed within the first 3 weeks; intervention is generally only indicated for WON with clear demarcation.[10][15]
- Infected necrosis (in either ANC or WON) may be suspected clinically when patients deteriorate or fail to improve after 7–10 days, and can be presumed by the presence of extraluminal gas on CECT (highly specific but only ~50% sensitive). Percutaneous fine-needle aspiration for culture is now used selectively; current guidelines recommend clinical judgment as the primary basis for diagnosing infection.[15][1]
Other local complications include abdominal compartment syndrome, gastric outlet dysfunction, splenic or portal vein thrombosis, pseudoaneurysm, intestinal ischemia, and colonic necrosis.[5][8]
Clinical Pearls and Pitfalls
High-yield pearls
- The 48-hour threshold for organ failure is the single most important determinant separating moderately severe from severe acute pancreatitis.[1][7][8]
- Severity classification is retrospective by nature and cannot be fully determined at admission; serial reassessment is mandatory.[7]
- Not all necrosis is equal: peripancreatic-only necrosis has a better prognosis than combined pancreatic plus peripancreatic necrosis.[4][3]
- "Pseudocyst" is overdiagnosed — many collections labeled as pseudocysts are actually WON containing solid necrotic debris, which can lead to inappropriate management (simple drainage instead of necrosectomy).[10][11]
- Extraluminal gas on CT is highly specific but only ~50% sensitive for infected necrosis; its absence does not exclude infection.[15]
Common pitfalls
- Performing CT too early (within 48–72 hours) may miss necrosis and lead to underclassification of disease severity.[10][2][13]
- Equating morphologic and severity classifications is inaccurate: interstitial edematous pancreatitis is usually mild, and necrotizing pancreatitis is usually moderately severe or severe, but these are separate classification axes.[4][1]
- Using abandoned terminology such as "pancreatic abscess," "phlegmon," or "acute pseudocyst" creates confusion and does not correspond to the current four-collection classification.[11][2]
- The 4-week rule for WON is not absolute — WON can develop earlier in a significant minority of patients; clinical and imaging assessment should guide intervention timing.[10]
- A negative fine-needle aspiration does not exclude infected necrosis; clinical deterioration after 7–10 days should prompt consideration of infected necrosis regardless of FNA results.[15]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 Banks PA, Bollen TL, Dervenis C; et al. (2013). "Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus". Gut. 62 (1): 102–11. doi:10.1136/gutjnl-2012-302779.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Thoeni RF (2012). "The revised Atlanta classification of acute pancreatitis: its importance for the radiologist and its effect on treatment". Radiology. 262 (3): 751–64. doi:10.1148/radiol.11110947.
- ↑ 3.0 3.1 3.2 3.3 Expert Panel on Gastrointestinal Imaging, Porter KK, Zaheer A; et al. (2019). "ACR Appropriateness Criteria® Acute Pancreatitis". J Am Coll Radiol. 16 (11S): S316–S330. doi:10.1016/j.jacr.2019.05.017.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 Tenner S, Vege SS, Sheth SG; et al. (2024). "American College of Gastroenterology guidelines: management of acute pancreatitis". Am J Gastroenterol. 119 (3): 419–437. doi:10.14309/ajg.0000000000002645.
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 Mederos MA, Reber HA, Girgis MD (2021). "Acute pancreatitis: a review". JAMA. 325 (4): 382–390. doi:10.1001/jama.2020.20317.
- ↑ 6.0 6.1 Wu BU, Banks PA (2013). "Clinical management of patients with acute pancreatitis". Gastroenterology. 144 (6): 1272–81. doi:10.1053/j.gastro.2013.01.075.
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 Trikudanathan G, Yazici C, Evans Phillips A, Forsmark CE (2024). "Diagnosis and management of acute pancreatitis". Gastroenterology. 167 (4): 673–688. doi:10.1053/j.gastro.2024.02.052.
- ↑ 8.0 8.1 8.2 8.3 8.4 8.5 8.6 Boxhoorn L, Voermans RP, Bouwense SA; et al. (2020). "Acute pancreatitis". Lancet. 396 (10252): 726–734. doi:10.1016/S0140-6736(20)31310-6.
- ↑ 9.0 9.1 Aaron AE, Amabile A, Andolfi C; et al. (2021). Gastrointestinal Surgical Emergencies. American College of Surgeons.
- ↑ 10.00 10.01 10.02 10.03 10.04 10.05 10.06 10.07 10.08 10.09 10.10 Trikudanathan G, Wolbrink DRJ, van Santvoort HC; et al. (2019). "Current concepts in severe acute and necrotizing pancreatitis: an evidence-based approach". Gastroenterology. 156 (7): 1994–2007.e3. doi:10.1053/j.gastro.2019.01.269.
- ↑ 11.0 11.1 11.2 11.3 11.4 Foster BR, Jensen KK, Bakis G, Shaaban AM, Coakley FV (2016). "Revised Atlanta classification for acute pancreatitis: a pictorial essay". Radiographics. 36 (3): 675–87. doi:10.1148/rg.2016150097.
- ↑ Garg PK, Singh VP (2019). "Organ failure due to systemic injury in acute pancreatitis". Gastroenterology. 156 (7): 2008–2023. doi:10.1053/j.gastro.2018.12.041.
- ↑ 13.0 13.1 13.2 Milano RV, Morneault-Gill K, Kamal HY, Barkin JA, Chadwick CB (2024). "Pancreatitis in cystic fibrosis: presentation, medical and surgical management, and the impact of modulator therapies". Pediatr Pulmonol. 59 (Suppl 1): S53–S60. doi:10.1002/ppul.26958.
- ↑ 14.0 14.1 14.2 Muthusamy VR, Chandrasekhara V, Acosta RD; et al. (2016). "The role of endoscopy in the diagnosis and treatment of inflammatory pancreatic fluid collections". Gastrointest Endosc. 83 (3): 481–8. doi:10.1016/j.gie.2015.11.027.
- ↑ 15.0 15.1 15.2 15.3 Maurer LR, Fagenholz PJ (2023). "Contemporary surgical management of pancreatic necrosis". JAMA Surg. 158 (1): 81–88. doi:10.1001/jamasurg.2022.5695.